IDEAYA Biosciences, Inc.

Executive Summary

IDEAYA Biosciences is a precision oncology company focused on developing targeted therapies for genetically defined cancers through synthetic lethality approaches. The company recently strengthened its balance sheet with a $300 million equity offering, providing ample runway to advance its pipeline of novel small molecule inhibitors. Key programs include IDE397, a MAT2A inhibitor targeting MTAP-deleted tumors, and IDE196, a PKC inhibitor for GNAQ/11-mutant uveal melanoma and other indications. Both programs are in Phase 1/2 development, with early clinical data suggesting monotherapy activity and a favorable safety profile. IDEAYA is also exploring combination strategies to expand the therapeutic potential of its pipeline, including combinations with checkpoint inhibitors and other targeted agents. Looking ahead, IDEAYA is well-positioned to deliver multiple value-inflection catalysts over the next 12-18 months. The company expects to report dose-expansion data from its Phase 2 portion of the IDE397 trial, which could validate the synthetic lethality hypothesis in a larger patient population. Additionally, the ongoing dose-escalation and expansion of IDE196 in combination with other agents may provide early activity signals. With a strong cash position and a focused pipeline, IDEAYA offers investors exposure to high-risk, high-reward precision oncology assets. However, clinical-stage biotech remains inherently risky, and failure to meet endpoints could significantly impact the stock.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 dose-expansion data for IDE397 in MTAP-deleted solid tumors60% success
• Q3 2026Initial data from IDE196 combination study with checkpoint inhibitor55% success
• Q3 2026IND filing for new MAT2A combination or next-generation program70% success